51 Influenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine are Highly Cost Effective in Canada

Author: Roy, Bertrand ; Nguyen, Van Hung

AbstractBackgroundInfluenza vaccination with quadrivalent egg-based vaccines (QIVe) in adults ≥ 65 years may be less effective due to immunosenescence. An MF59®-adjuvanted trivalent influenza vaccine (aTIV) has been developed to provide stronger, broader and longer protection in older adults. For the younger age groups, lower effectiveness may be associated to the mutagenesis of influenza viruses that are propagated in eggs. A cell- based quadrivalent influenza vaccine (QIVc) was developed to improve the vaccine effectiveness by eliminating egg-adaptation.ObjectivesThe objective of this analysis was to evaluate the potential public health impact on the utilization of both vaccines in Canada.Design/MethodsAn SEIR dynamic-transmission model was created and adapted to four influenza strains for the 2013-2019 seasons. Strain-specific circulation was obtained from Canada’s national surveillance system. Influenza incidence estimates were calibrated using CDC published data. The model used rVE from peer reviewed publications for QIVc and aTIV showing superiority to QIVe vaccines. Frequency of egg-based genetic changes were estimated from a published review of Crick Institute reports. Estimates of specific vaccines efficacy and economic assumptions were derived from the published literature. Different vaccination scenarios, based on the provincial vaccination programs, were modelled.ResultsReplacing QIVe with QIVc in subjects 6 months-64 years led to an annual reduction of 462 156 symptomatic cases; 58 122 GP visits; 40,871 emerging consultations; 3 788 hospitalizations and 662 deaths versus a QIVe-for-all scenario. The adoption of QIVc and aTIV will be highly cost effective over the use of QIVe. aTIV would also be more cost effective than QIVHD. Table 1 provides the detailed results for the others scenario. Sensitivity analyses confirmed the robustness of the assumptions used in the analysis.ConclusionThe greatest public health impact is obtained by using QIVc and aTIV in influenza vaccine programs in Canada versus other combinations of available vaccine.

100 Deals associated with Seqirus Canada, Inc.

100 Translational Medicine associated with Seqirus Canada, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Seqirus Canada, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 12 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing